OVATION Pharmaceuticals, Inc. Completes in-Licensing of ATryn(R) (antithrombin alfa) From GTC Biotherapeutics in the United States

DEERFIELD, Ill.--(BUSINESS WIRE)--OVATION Pharmaceuticals, Inc. announced today that it has completed its previously announced transaction to obtain the exclusive license for the commercialization and development of GTC Biotherapeutics’ ATryn® (antithrombin alfa) in the United States.